16.9 C
New York
Monday, September 25, 2023

Win For Pfizer? Seagen’s Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study

Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

158,198FansLike
395,950FollowersFollow
2,220SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x